Skip to main content Accessibility help
  • Print publication year: 2013
  • Online publication date: June 2013

Section 2 - Intervention options

Related content

Powered by UNSILO


1. FoxSH, KatzenschlagerR, LimSY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2011;26:S2–41.
2. FreedCR, GreenePE, BreezeRE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. New Engl J Med 2001;344:710–19.
3. OlanowCW, GoetzCG, KordowerJH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 2003;54:403–14.
4. OlanowCW, HauserRA, GaugerL, et al. The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 1995;38:771–7.
5. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Parkinson Study Group. Ann Neurol 1996;39:29–36.
6. ShoulsonI, OakesD, FahnS, et al; Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604–12.
7. PalhagenS, HeinonenE, HagglundJ, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006;66:1200–6.
8. ZhaoYJ, WeeHL, AuWL, et al. Selegiline use is associated with a slower progression in early Parkinson’s disease as evaluated by Hoehn and Yahr Stage transition times. Parkinsonism Relat Disord 2011;17:194–7.
9. OlanowCW, RascolO, HauserR, et al. ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. New Engl J Med 2009;361:1268–78.
10. Movement Disorder Society. Anticholinergic therapies in the treatment of Parkinson’s disease. Management of Parkinson’s disease: an evidence-based review. Mov Disord 2002;17:S7–12.
11. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000;284:1931–8.
12. RascolO, BrooksDJ, KorczynAD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484–91.
13. AhlskogJE, MuenterMD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448–58.
14. JennerP. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004;62:S47–55.
15. OlanowCW, ObesoJA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson’s disease: implications for the early use of COMT inhibitors. Neurology 2000;55:S72–7; discussion S78–81.
16. StocchiF, RascolO, KieburtzK, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68:18–27.
17. Movement Disorder Society. Amantadine and other antiglutamate agents: management of Parkinson’s disease. Management of Parkinson’s disease: an evidence-based review. Mov Disord 2002;17:S13–22.
18. SchapiraAH, OlanowCW. Drug selection and timing of initiation of treatment in early Parkinson’s disease. Ann Neurol 2008;64:S47–55.
19. CrawfordP, ZimmermanEE. Differentiation and diagnosis of tremor. Am Fam Physician 2011;83:697–702.
20. ZesiewiczTA, ElbleRJ, LouisED, et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology 2011;77:1752–5.
21. FahnS, JankovicJ. Tremors: diagnosis and treatment. In FahnS, JankovicJ, eds. Principles and Practice of Movement Disorders. Philadelphia: Churchill Livingstone Elsevier, 2007;451–78.
22. FahnS, JankovicJ. Dystonia: phenomenology, classification, etiology, pathology, biochemistry and genetics. In: FahnS, JankovicJ, eds. Principles and Practice of Movement Disorders. Philadelphia: Churchill Livingstone Elsevier, 2007;307–44.
23. ManjiH, HowardRS, MillerDH, et al. Status dystonicus: the syndrome and its management. Brain 1998;121:243–52.
24. TarsyD, SimonDK. Dystonia. New Engl J Med 2006;355:818–29.
25. AlbaneseA, AsmusF, BhatiaKP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 2011;18:5–18.
26. BalashY, GiladiN. Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol 2004;11:361–70.
27. AlbaneseA, BarnesMP, BhatiaKP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 2006;13:433–44.
28. BraininM, BarnesM, BaronJC, et al; Guideline Standards Subcommittee of the EFNS Scientific Committee. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004. Eur J Neurol 2004;11:577–81.
29. WalkerFO. Huntington’s disease. Lancet 2007;369:218–28.
30. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366–72.
31. MestreTA, FerreiraJJ. An evidence-based approach in the treatment of Huntington’s disease. Parkinsonism Relat Disord 2011 Dec 15.
32. RossCA, TabriziSJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011;10:83–98.
33. CuboE, ShannonKM, TracyD, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology 2006;67:1268–71.


1. FordB. Pain in Parkinson’s disease. Mov Disord 2010;25:S98–103.
2. LangAE, ChenR. Dystonia in complex regional pain syndrome type I. Ann Neurol 2010;67:412–14.
3. SnyderBJ, LozanoAM. Surgery for non-dopaminergic and non-motor feature of Parkinson’s disease. In OlanowCW, StocchiF, LangAE, eds. Parkinson’s Disease: Non-Motor and Non-Dopaminergic Features. Oxford, Blackwell Publishing Ltd, 2011.
4. DeuschlG, Schade-BrittingerC, KrackP, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. New Engl J Med 2006;355:896–908.
5. WeaverFM, FollettK, SternM, et al. Bilateral deep brain stimulation vs. best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301:63–73.
6. WilliamsA, GillS, VarmaT, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010;9:581–91.
7. WeaverF, FollettK, HurK, IppolitoD, SternM. Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurosurg 2005;103:956–67.
8. Kleiner-FismanG, HerzogJ, FishmanGN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006;21:S290–304.
9. ParsonsTD, RogersSA, BraatenAJ, WoodsSP, TrosterAI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson’s disease: a meta-analysis. Lancet Neurol 2006;5:578–88.
10. St GeorgeRJ, NuttJG, BurchielKJ, HorakFB. A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. Neurology 2010;75:1292–9.
11. St GeorgeRJ, Carlson-KuhtaP, BurchielKJ, et al. The effects of subthalamic and pallidal deep brain stimulation on postural responses in patients with Parkinson disease. J Neurosurg 2012;116:1347–56.
12. GuridiJ, ObesoJA, Rodriguez-OrozMC, LozanoAA, ManiqueM. L-dopa-induced dyskinesia and stereotactic surgery for Parkinson’s disease. Neurosurgery 2008;62:311–23; discussion 323–5.
13. MoroE, LozanoAM, PollakP, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson’s disease. Mov Disord 2010;25:578–86.
14. HausdorffJM, GruendlingerL, ScollinsL, O’HerronS, TarsyD. Deep brain stimulation effects on gait variability in Parkinson’s disease. Mov Disord 2009;24:1688–92.
15. JohnsenEL, MogensenPH, SundeNA, OstergaardK. Improved asymmetry of gait in Parkinson’s disease with DBS: gait and postural instability in Parkinson’s disease treated with bilateral deep brain stimulation in the subthalamic nucleus. Mov Disord 2009;24:590–7.
16. OkunMS, FernandezHH, WuSS, et al. Cognition and mood in Parkinson’s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 2009;65:586–95.
17. CastelliL, RizziL, ZibettiM, et al. Neuropsychological changes 1-year after subthalamic DBS in PD patients: a prospective controlled study. Parkinsonism Relat Disord 2010;16:115–18.
18. YorkMK, DulayM, MaciasA, et al. Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2008;79:789–95.
19. ZangagliaR, PacchettiC, PasottiC, et al. Deep brain stimulation and cognitive functions in Parkinson’s disease: a three-year controlled study. Mov Disord 2009;24:1621–8.
20. VoonV, KrackP, LangAE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s disease. Brain 2008;131:2720–8.
21. WittK, DanielsC, ReiffJ, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study. Lancet Neurol 2008;7:605–14.
22. ParkJH, ChungSJ, LeeCs, JeonSR. Analysis of hemorrhagic risk factors during deep brain stimulation surgery for movement disorders: comparison of the circumferential paired and multiple electrode insertion methods. Acta Neurochir (Wien) 2011;153:1573–8.
23. ZrinzoL, FoltynieT, LimousinP, HarizMI. Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review. J Neurosurg 2012;116:84–94.
24. SillayKA, LarsonPS, StarrPA. Deep brain stimulator hardware-related infections: incidence and management in a large series. Neurosurgery 2008;62:360–7.
25. PiacentinoM, PilleriM, BartolomeiL. Hardware-related infections after deep brain stimulation surgery: review of incidence, severity and management in 212 single-center procedures in the first year after implantation. Acta Neurochir (Wien) 2011;153:2337–41.
26. TierneyTS, SankarT, LozanoAM. Deep brain stimulation emerging indications. Prog Brain Res 2011;194C:83–95.
27. AarslandD, MarshL, SchragA. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord 2009;24:2175–86.
28. SohSE, MorrisME, McGinleyJL. Determinants of health-related quality of life in Parkinson’s disease: a systematic review. Parkinsonism Relat Disord 2011;17:1–9.
29. MerolaA, ZibettiM, AngrisanoS, et al. Parkinson’s disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. Brain 2011;134:2074–84.
30. HelyMA, ReidWG, AdenaMA, HallidayGM, MorrisJG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837–44.
31. MorrisME, IansekR, GalnaB. Gait festination and freezing in Parkinson’s disease: pathogenesis and rehabilitation. Mov Disord 2008;23:S451–60.
32. PahapillPA, LozanoAM. The pedunculopontine nucleus and Parkinson’s disease. Brain 2000;123:1767–83.
33. StefaniA, LozanoAM, PeppeA, et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s disease. Brain 2007;130:1596–607.
34. MazzoneP, SposatoS, InsolaA, DilazzaroV, ScarnatiE. Stereotactic surgery of nucleus tegmenti pedunculopontine [corrected]. Br J Neurosurg 2008;22:S33–40.
35. PereiraEA, MuthusamyKA, De PenningtonN, JointCA, AzizTZ. Deep brain stimulation of the pedunculopontine nucleus in Parkinson’s disease. Preliminary experience at Oxford. Br J Neurosurg 2008;22:S41–4.
36. FerrayeMU, DebuB, FraixV, et al. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson’s disease. Brain 2010;133:205–14.
37. MoroE, HamaniC, PoonYY, et al. Unilateral pedunculopontine stimulation improves falls in Parkinson’s disease. Brain 2010;133:215–24.
38. RajputAH, OffordKP, BeardCM, KurlandLT. Essential tremor in Rochester, Minnesota: a 45-year study. J Neurol Neurosurg Psychiatry 1984;47:466–70.
39. LouisED, FerreiraJJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord 2010;25:534–41.
40. BrodkeyJA, TaskerRR, HamaniC, et al. Tremor cells in the human thalamus: differences among neurological disorders. J Neurosurg 2004;101:43–7.
41. KaneA, HutchisonWD, HodaieM, LozanoAM, DostrovskyJO. Enhanced synchronization of thalamic theta band local field potentials in patients with essential tremor. Exp Neurol 2009;217:171–6.
42. BenabidAL, PollakP, GervasonC, et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991;337:403–6.
43. PahapillPA, LevyR, DostrovskyJO, et al. Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor. Ann Neurol 1999;6:249–52.
44. DeuschlG, BainP, PrinM, et al. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord 1998;13:2–23.
45. SchragA, MunchauA, BhatiaKP, QuinnNP, Marsden, CP. Essential tremor: an overdiagnosed condition?J Neurol 2000;247:955–9.
46. DiederichNJ, Verhagen MetmanL, BakayRA, AleschF. Ventral intermediate thalamic stimulation in complex tremor syndromes. Stereotact Funct Neurosurg 2008;86:167–72.
47. EspayAJ, DukerAP, ChenR, et al. Deep brain stimulation of the ventral intermediate nucleus of the thalamus in medically refractory orthostatic tremor: preliminary observations. Mov Disord 2008;23:2357–62.
48. MorishitaT, FooteKD, HagIU, et al. Should we consider Vim thalamic deep brain stimulation for select cases of severe refractory dystonic tremor. Stereotact Funct Neurosurg 2010;88:98–104.
49. TorresCV, MoroE, Lopez-RiosAL, et al. Deep brain stimulation of the ventral intermediate nucleus of the thalamus for tremor in patients with multiple sclerosis. Neurosurgery 2010;67:646–51.
50. DeuschlG, RaethjenJ, HellriegelH, ElbleR. Treatment of patients with essential tremor. Lancet Neurol 2011;10:148–61.
51. LouisED, BarnesL, AlbertSM, et al. Correlates of functional disability in essential tremor. Mov Disord 2001;16:914–20.
52. RajputA, RobinsonCA, RajputAH. Essential tremor course and disability: a clinicopathologic study of 20 cases. Neurology 2004;62:932–6.
53. HarizGM, BlomstedtP, KoskineneLO. Long-term effect of deep brain stimulation for essential tremor on activities of daily living and health-related quality of life. Acta Neurol Scand 2008;118:387–94.
54. TaskerRR. Deep brain stimulation is preferable to thalamotomy for tremor suppression. Surg Neurol 1998;49:145–54.
55. SchuurmanPR, BoschDA, BossutyPMM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. New Engl J Med 2000;342:461–8.
56. RichterEO, HamaniC, et al. Efficacy and complications of deep brain stimulation for movement disorders. In BakayRA, ed. Movement Disorder Surgery: The Essentials. New York, Thieme Medical Publishers, Inc. 2009.
57. KumarR, LozanoAM, SimeE, LangAE. Long-term follow-up of thalamic deep brain stimulation for essential and parkinsonian tremor. Neurology 2003;61:1601–4.
58. PahwaR, LyonsKE, WilkinsonSB, et al. Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg 2006;104:506–12.
59. ZhangK, BhatiaS, OhMY, et al. Long-term results of thalamic deep brain stimulation for essential tremor. J Neurosurg 2010;112:1271–6.
60. OhMY, HodaieM, KimSH, et al. Deep brain stimulator electrodes used for lesioning: proof of principle. Neurosurgery 2001;49:363–9.
61. YuH, HederaP, FangJ, DavisTL, KonradPE. Confined stimulation using dual thalamic deep brain stimulation leads rescues refractory essential tremor: report of three cases. Stereotact Funct Neurosurg 2009;87:309–13.
62. MurataJ, KitagawaM, UesugiH, et al. Electrical stimulation of the posterior subthalamic area for the treatment of intractable proximal tremor. J Neurosurg 2003;99:708–15.
63. LindG, SchechtmannG, LindC, et al. Subthalamic stimulation for essential tremor. Short- and long-term results and critical target area. Stereotact Funct Neurosurg 2008;86:253–8.
64. OyamaG, FooteKD, HwynnN, et al. Rescue leads: a salvage technique for selected patients with a suboptimal response to standard DBS therapy. Parkinsonism Relat Disord 2011;17:451–5.
65. TsuiJK, EisenA, StoesslAJ, CalneS, CalneDB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245–7.
66. KumarR, DagherA, HutchisonWD, LangAE, LozanoAM. Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation. Neurology 1999;53:871–4.
67. CoubesP, RoubertieA, et al. Treatment of DYT1-generalised dystonia by stimulation of the internal globus pallidus. Lancet 2000;355: 2220–1.
68. VercueilL, PollakP, FraixV, et al. Deep brain stimulation in the treatment of severe dystonia. J Neurol 2001;248:695–700.
69. SimpsonDM, BlitzerA, BrashearA, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1699–706.
70. OzeliusLJ, LubarrN, BressmanSB. Milestones in dystonia. Mov Disord 2011;26:1106–26.
71. DefazioG, BerardelliA, HallettM. Do primary adult-onset focal dystonias share aetiological factors?Brain 2007;130:1183–93.
72. Iwata, M. MRI pathology of basal ganglia in dystonic disorders. Adv Neurol 1993;60:535–9.
73. PennRD, KroinJS. Continuous intrathecal baclofen for severe spasticity. Lancet 1985;2:125–7.
74. AlbrightAL, FersonSS. Intrathecal baclofen therapy in children. Neurosurg Focus 2006;21:e3.
75. JankovicJ, HunterC, DolimbekBZ, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 2006;67:2233–5.
76. AlbaneseA, AsmusF, BhatiaKP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 2011;18:5–18.
77. KupschA, BeneckeR, MullerJ, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. New Engl J Med 2006;355:1978–90.
78. MuellerJ, SkogseidIM, BeneckeR, et al. Pallidal deep brain stimulation improves quality of life in segmental and generalized dystonia: results from a prospective, randomized sham-controlled trial. Mov Disord 2008;23:131–4.
79. KissZH, Doig-BeyaertK, EliasziwM, et al. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain 2007;130:2879–86.
80. DamierP, ThoboisS, WitjasT, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry 2007;64:170–6.
81. EltahawyHA, Saint-CyrJ, GilaniN, LangAe, LozanoAM. Primary dystonia is more responsive than secondary dystonia to pallidal interventions: outcome after pallidotomy or pallidal deep brain stimulation. Neurosurgery 2004;54:613–21.
82. AndrewsC, Aviles-OlmosI, HarizM, FoltynieT. Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes. J Neurol Neurosurg Psychiatry 2010;81:1383–9.
83. TierneyTS, SankarT, et al. Some recent trends and further promising directions in functional neurosurgery. Acta Neurol Scand 2012;in press.


1. NaumannM, SoY, ArgoffCE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1707–14.
2. GellerBD, HallettM, RavitsJ. Botulinum toxin therapy in hemifacial spasm: clinical and electrophysiological studies. Muscle & Nerve 1989;12:716–22.
3. DykstraDD, SidiAA. Treatment of Detrusor Sphincter Dyssinergia with botulinum A toxin: a double blind study. Arch Phys Med Rehabil 1990:71:24–6.
4. BlackieJD, LeesAJ. Botulinum toxin treatment in spasmodic torticollis. J Neurol, Neurosurg Psychiatr 1990;53:640–3.
5. BlitzerA, BrinMF. Laryngeal dystonia a series with botulinum toxin therapy. Ann Otol Rhinol Laryngol 1991;100:85–9.
6. CuiM, KhanijouS, RubinoJ, AokiKR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125–33.
7. FreundBJ, SchwartzM. Treatment of chronic cervical associated headache with botulinum toxin A: a pilot study. Headache 2000;40:231–6.
8. Lang, A. Botulinum toxin type A for the management of cervicothoracic and cervicobrachial pain: treatment rationale and open label results in 25 patients. American Journal of Pain Management, 2004;14:13–23.
9. BhaktaBB, CozensJA, BamfordJM, ChamberlainMA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996;61:30–5.
10. FockJ, GaleaMP, StillmanBC, RawickiB, ClarkM. Functional outcome following botulinum toxin A injection to reduce spastic equinus in adults with traumatic brain injury. Brain Injury 2004;18:57–63.
11. SimpsonDM, AlexanderDN, O’BrienCF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo controlled trial. Neurology 1996;46:1306–10.
12. Al-KhodairyAT, GobeletC, RossierAB. Has botulinum toxin type A a place in the treatment of spasticity in spinal cord injury patients?Spinal Cord 1998;36:854–8.
13. BarnesM. Botulinum toxin – mechanisms of action and clinical use in spasticity. J Rehabil Med 2003;41:S56–9.
14. RossettoO. How botulinum toxins work. In: MooreAP, NaumannNP, eds. Handbook of Botulinum Toxin Treatment, 2nd edn. Oxford: Blackwell Scientific Press, 2003; 9–27.
15. DollyJO, AokiKR. The structure and mode of action of different botulinum toxins. Eur J Neurol 2006;13:S(4)1–9.
16. GazeraniP, PedersonNS, StaahlC, DrewesA, Arendt-NielsenL. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009;141:60–9.
17. BrinMF, LyonsKE, DoucetteJ, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001;56:1523–8.
18. JankovicJ, OrmanJ. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987;37:616–23.
19. TsuiJK, EisenA, StoesslAJ, CalneS, CalneDB. Doubleblind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245–7.
20. FruehBR, FeltDP, WojnoTH, MuschDC. Treatment of blepharospasm with botulinum toxin: a preliminary report. Arch Ophthalmol 1984;102:1464–8.
21. FahnS. Concept and classification of dystonia. Adv Neurol 1988;50:1–8.
22. SangerTD, DelgadoMR, Gaebler-SpiraD, et al. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003;111:89–97.
23. Aoki, KR, RanouxD, WisselJ. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Nuerol 2006;13:S(4)10–19.
24. de PaivaA, MeunierFA, MolgoJ, AokiKR, DollyJO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999;96:3200–5.
25. NovakI, CampbellL, BoyceM, FungVS. Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement. Eur J Neurol 2010;17:S(2)94–108.
26. AdamOR, JankovicJ. Treatment of dystonia. Parkinsonism Relat Disord, 2007;13:S362–8.
27. SheffieldJK, JankovicJ. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson’s disease. Expert Rev Neurotherapeutics, 2007;7:637–47.
28. KenneyC, JankovicJ. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 2008;115:585–91.
29. TsuiJK, BhattM, CalneS, CalneDB. Botulinum toxin in the treatment of writer’s cramp: a double blind study. Neurology 1993;43:183–5.
30. SchueleS, JabuschHC, LedermanRJ, AltenmullerE. Botulinum toxin injections in the treatment of musician’s dystonia. Neurology 2005;64:341–3.
31. DeuschlG, BainP, BrinM. Consensus statement of the Movement Disorder Society on tremor. Ad Hoc Scientific Committee. Mov Disord 1998;13:3–23.
32. JankovicJ. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009;8:844–56.
33. JankovicJ, SchwartzK, ClemenceW, AswadA, MordauntJ. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 1996;11:250–6.
34. GraciesJM, Simpson, D. Spastic dystonia. In BrinMF, ComellaC, JankovicJ, eds. Dystonia: Etiology, Clinical Features, and Treatment. Philadelphia: Lippincott, Williams and Wilkins, 2004, p. 195.
35. CordivariC, MisraVP, CataniaS, LeesAJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord 2001;16:907–13.
36. SheeanG, LanninNA, Turner-StokesL, et al. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol 2010;17:S(2)74–93.
37. OlverJ, EsquenaziA, FungVS, et al. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. Eur J Neurol 2010;17:S(2)57–73.
38. PacchettiC, AlbaniG, MartignoniE, et al. “Off” painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord 1995;10:333–6.
39. LimousinP, MeminB, PollakP. Treatment of dystonia occurring in parkinsonian syndromes by botulinum toxin. Eur J Neurol 1997;37:66–7.
40. Denny-BrownD. The nature of apraxia. J Nerv Ment Dis 1958;126:9–31.
41. GurevicT, PeretzC, MooreO, WeizmannN, GiladiN. The effect of injecting botulinum toxin type A into the calf muscles on freezing of gait in Parkinson’s disease: a double blind placebo-controlled pilot study. Mov Disord 2007;22:880–3.
42. WielerM, CamicoliR, JonesCA, MartinWR. Botulinum toxin injections do not improve freezing of gait in Parkinson disease. Neurology 2005;65:626–8.
43. FernandezHH, LammonMC, TrieschmannME, FriedmanJH. Botulinum toxin type B for gait freezing in Parkinson’s disease. Med Sci Monit 2004;10:282–4.
44. SchneiderSA, EdwardsMJ, GrillSE, et al. Adult-onset primary lower limb dystonia. Mov Disord 2006;21:767–71.
45. SchneiderSA, EdwardsMJCordivariC, MacleodWN, BhatiaKP. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson s disease. Mov Disord 2006;21:1722–4.
46. KhaliliAA, HarmelMJ, ForsterS, BentonJG. Management of spasticity by selective peripheral nerve block with dilute phenol solutions in clinical rehabilitation. Arch Phys Med Rehabil 1964;45:513–19.
47. WoodKM. The use of phenol as a neurolytic agent: a review. Pain 1978;5:205–29.
48. FelsenthalG. Pharmacology of phenol in peripheral nerve blocks: a review. Arch Phys Med Rehab 1974;55:13–16.
49. GoochJL, PattonCP. Combining botulinum toxin and phenol to manage spasticity in children. Arch Phys Med Rehabil 2004;85:1121–4.
50. LeeJ, LeeYS. Percutaneous chemical nerve block with ultrasound-guided intraneural injection. Eur Radiol 2008;18:1506–12.
51. KirazliY, OnAY, KismaliB, AksitR. Comparison of phenol block and botulinus toxin in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil 1998:77;510–15.
52. GarlandDE, LucieRS, WatersRLCurrent uses of open phenol nerve block for adult acquired spasticity. Clin Orthop Rel Res 1982;165:217–22.
53. KeenanMA, TomasES, StoneL, GerstenLM. Percutaneous phenol block of the musculocutaneous nerve to control elbow flexor spasticity. J Hand Surg Am 1990;15:340–6.
54. BrunoG. Intrathecal alcohol block experiences on 41 cases. Paraplegia 1975;12:305–9.
55. JangSH, AhnSH, ParkSM, et al. Alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle to treat ankle spasticity in patients with hemiplegic stroke. Arch Phys Med Rehabil 2004;85:506–8.
56. Rawicki, H. Treatment of cerebral origin spasticity with continuous intrathecal baclofen delivered via an implantable pump: long term follow-up and review of 18 patients. J Neurosurg 1999;91:733–6.
57. MeythalerJM, Guin-RenfroeS, BrunnerRC, HadleyMN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 2001;32:2099–109.
58. WardAB. Long-term modification of spasticity. J Rehabil Med 2003;41:S60–5.
59. KorenkovAI, NiendorfWR, DarwishN, GlaeserE, GaabMR. Continuous intrathecal infusion of baclofen in patients with spasticity caused by spinal cord injuries. Neurosurg Rev 2002;25:228–30.
60. DykstraDD, MendezA, ChappuisD, et al. Treatment of cervical dystonia and focal hand dystonia by high cervical continuously infused intrathecal baclofen: a report of 2 cases. Arch Phys Med Rehabil 2005;86:830–3.
61. KroinJS, AliaA, YorkM, PennRD. The distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery 1993;33(2):226–30.
62. BrennanPM, WhittleIR. Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain. Br J Neurosurg 2008;22:508–19.
63. PennRD, KroinJL. Continuous intrathecal baclofen for severe spasticity. Lancet 1985;2:125–7.
64. NarayanRK, LoubserPG, JankovicJJ, DonovanWH, BontkeCF. Intrathecal baclofen for intractable axial dystonia. Neurology 2001;41:1141–2.
65. PennRD, GianinoJM, YorkMM. Intrathecal baclofen for motor disorders. Mov Disord 1995:10;675–7.
66. AlbrightAL, BarryMJ, ShafronDH, FersonSS. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2001;43:652–7.
67. PanouriasIG, ThemistocleousM, SakasDE. Intrathecal baclofen in current neuromodulatory practice: established indications and emerging applications. Acta Neurochirurgica. Supplement 2007;97(Pt 1):145–54.
68. KyriagisM, Grattan-SmithP, ScheinbergA, et al. Status dystonicus and Hallervorden-Spatz disease: treatment with intrathecal baclofen and pallidotomy. J Paediatr Child Health 2004;40:322–5.
69. KammC. Early onset torsion dystonia (Oppenheim’s dystonia). Orphanet J Rare Dis 2006;1:48–54.
70. MoreletA, Gagneux-LemoussuL, BrochotP, et al. Tonic dystonia: an uncommon complication of reflex sympathetic dystrophy syndrome. A review of five cases. Joint Bone Spine 2005;72:260–2.
71. ZunigaRE, PereraS, AbramSE. Intrathecal baclofen: a useful agent in the treatment of well-established complex regional pain syndrome. Reg Anesth Pain Med 2002;27:90–3.
72. LundS, LundbergA, VyklickyL. Inhibitatory action from the flexor reflex afferents on transmission to Ia afferents. Acta Physiol Scand 1965;64:345–55.
73. van HiltenBJ, van de BeekWJ, HoffJI, VoormolenJH, DelhaasEM. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. New Eng J Med 2000;343:625–31.
74. BhidayasiriR, TarsyD. Treatment of dystonia. Exp Rev Neurotherapeutics 2006;6:863–86.
75. HungSW, HamaniC, LozanoAM, et al. Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. Neurology 2007;68:457–9.
76. McLaughlinJ, BjornsonK, TemkinN, et al. Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. Dev Med Child Neurol 2002;44:17–25.
77. TedroffK, LowingK, JacobsonDN, AstromE. Does loss of spasticity matter? A 10-year follow-up after selective dorsal rhizotomy in cerebral palsy. Dev Med Child Neurol 2011;53:724–9.
78. Fuller, D. Surgery in the management of spasticity. In BrashearA, ElovicE, eds. Spasticity Diagnosis and Management, New York: Demos Medical Publishing, 2011;243–70.
79. ReimersJ. Functional changes in the antagonists after lengthening the agonists in cerebral palsy. I triceps surae lengthening. Clin Orthop Relat Res 1990;253:30–4.
80. OmerGE, CapenDA. Proximal row carpectomy with muscle transfers for spastic paralysis. J Hand Surg Am 1976:1:197–204.
81. FehlingsD, NovakI, BerweckS, et al. Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement. Eur J Neurol 2010;17:S(2)57–73.
82. LoveSC, NovakI, KentishM, et al. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol 2010;17:S(2)9–37.
83. LevyCE, GiuffridaC, RichardsL, et al. Botulinum toxin A, evidence-based exercise therapy, and constraint-induced movement therapy for upper-limb hemiparesis attributable to stroke: a preliminary study. Am J Phys Med Rehabil 2007;86:696–706.
84. SunSF, HsuCW, HwangCW, et al. Application of combined botulinum toxin type A and modified constraint-induced movement therapy for an individual with chronic upper-extremity spasticity after stroke. Phys Ther 2006;86:1387–97.
85. HoareB, ImmsC, CareyL, WasiakJ. Constraint-induced movement therapy in the treatment of the upper limb in children with hemiplegic cerebral palsy: a Cochrane systematic review. Clin Rehabil 2007;21:675–85.
86. GiovannelliM, BorrielloG, CastriP, et al. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 2007;21:331–7.
87. JohnsonCA, BurridgeJH, StrikePW, WoodDE, SwainID. The effect of combined use of botulinum toxin type A and functional electric stimulation in the treatment of spastic drop foot after stroke: a preliminary investigation. Arch Phys Med Rehabil 2004;85:902–9.
88. FarinaS, MiglioriniC, GandolfiM, et al. Combined effects of botulinum toxin and casting treatments on lower limb spasticity after stroke. Funct Neurol 2008;23:87–91.
89. VerplanckeD, SnapeS, SalisburyCF, JonesPW, WardAB. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil 2005;19:117–25.
90. BylNN, MckenzieA. Treatment effectiveness for patients with a history of repetitive hand use and focal hand dystonia: a planned, prospective follow-up study. J Hand Ther 2000;13:289–301.
91. ZeunerKE, Bara-JimenezW, NoguchiPS, et al. Sensory training for patients with focal hand dystonia. Ann Neurol 2002;51:593–8.
92. LanninNA, CusickA, McCluskeyA, HerbertRD. Effects of splinting on wrist contracture after stroke: a randomized controlled trial. Stroke 2006;38:111–16.
93. MarossezkyJE, GurkaJA, BaguleyIJ. Splinting poststroke: the jury is still out. Stroke 2008;39:e46.
94. KatalinicOM, HarveyLA, HerbertRD. Effectiveness of stretch for the treatment and prevention of contractures in people with neurological conditions: a systematic review. Phys Ther 2011;91:11–24.
95. AzherSN, JankovicJ.Camptocormia: pathogenesis, classification, and response to therapy. Neurology 2005;65(3):355–359.
96. GiladiN, MonigmanS.Botulinum toxin injections to one leg alleviate freezing of gait in a patient with Parkinson’s disease. Mov Disord 1997;12:1085–6.